Reprogramming T cells to make safer, smarter CAR-T cancer therapy
Official title: Reprogramming T cell function with multiplexed genome engineering to develop next-generation immunotherapy
Funded at Wistar Institute · NIH-11377722 · Data updated 2026-11-12
A new NIH grant aims to make CAR-T cell therapy safer and more effective for solid cancers by letting engineered T cells tune themselves and by blocking the tumor’s immune-suppressing signals.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wistar Institute NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | March 8, 2024 |
| Project end | May 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $249,000 |
| NIH project number | 5R00CA282989-04 |
| Project ID | NIH-11377722 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are patients with advanced solid tumors who may be eligible for future immunotherapy trials.
✕Less likely to help
Patients with cancers not driven by immune evasion or those unable to tolerate immunotherapy may not benefit.
What this research studies
This project focuses on advanced cancer and develops two complementary approaches: self-regulating CAR-T cells that adjust their activity in response to real-time signals, and engineered protein tools that remove proteins in the tumor environment that suppress immune responses. By combining intrinsic control of T cells with extrinsic disruption of the tumor’s defenses, the work seeks to enhance anti-tumor activity while reducing side effects. The study uses translational approaches that could move from lab models toward clinical testing, aiming to improve outcomes for patients with solid tumors. Overall, the research is designed to unlock safer, more powerful immunotherapies for cancers that have been difficult to treat.
Why it matters
Potential benefit: If successful, patients could receive more effective CAR-T therapies with fewer toxicities, especially for solid tumors.
How similar studies have gone: Previous work with CAR-T cells shows promise in blood cancers, but solid tumors remain challenging, making this combination approach novel.
Where this research is happening
-
Wistar Institute
Philadelphia, United States Active
Researchers
- Principal investigator: Zhou, Xiaoyu — Wistar Institute
- Study coordinator: Zhou, Xiaoyu
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.